Renu Singh
Overview
Explore the profile of Renu Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
1071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jogiraju V, Pawar P, Yager J, Ling J, Shen G, Chiu A, et al.
Lancet
. 2025 Mar;
PMID: 40086460
Background: Long-acting antiretrovirals can address barriers to HIV pre-exposure prophylaxis (PrEP), such as stigma and adherence. In two phase 3 trials, twice-yearly subcutaneous lenacapavir was safe and highly efficacious for...
2.
Shamsad A, Gautam T, Singh R, Banerjee M
World J Clin Pediatr
. 2025 Mar;
14(1):99231.
PMID: 40059904
Gestational diabetes mellitus (GDM) is a metabolic disorder, recognised during 24-28 weeks of pregnancy. GDM is linked with adverse newborn outcomes such as macrosomia, premature delivery, metabolic disorder, cardiovascular, and...
3.
Somarajan B, Singh R, Panigrahi A, Sharma A, Gupta S, Wiggs J, et al.
Ophthalmic Genet
. 2025 Feb;
:1-5.
PMID: 39995314
Purpose: To analyze exome sequence data from Indian cases with primary congenital glaucoma (PCG) for pathogenic variants. Materials/methods: In this cross-sectional observational study, ten consecutive, unrelated patients with a clinical...
4.
Ogbuagu O, Avihingsanon A, Segal-Maurer S, Wang H, Jogiraju V, Singh R, et al.
AIDS
. 2025 Feb;
PMID: 39912752
Objective: To assess efficacy, safety and pharmacokinetics (PK) of oral lenacapavir (LEN) when used as oral bridging (OB) between delayed subcutaneous (SC) LEN injections. Design: Posthoc analysis of participants in...
5.
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, et al.
J Infect Dis
. 2025 Jan;
PMID: 39873394
Background: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination...
6.
Singh R, Shelton M, Olson I, Ling J, West S, Levy J, et al.
Clin Pharmacol Drug Dev
. 2025 Jan;
PMID: 39844693
Lenacapavir is a potent, long-acting HIV-1 capsid inhibitor used in combination with other antiretrovirals to treat HIV-1 infection. The pharmacokinetics of orally administered drugs may be affected by food intake...
7.
Verma S, Yadav A, Venkatesh V, Jain A, Kumar M, Tripathi S, et al.
Indian J Med Res
. 2024 Dec;
160(5):501-505.
PMID: 39737512
Background & objectives The COVID-19 pandemic underscores the significance of vaccination in mitigating disease spread, with Covishield and Covaxin serving as pivotal vaccines in India. Breast milk, rich in vital...
8.
Shukla A, Singh R, Gupta A, Goel A, Tiwari K, Singh S
Cureus
. 2024 Dec;
16(11):e74571.
PMID: 39734992
Introduction Insulin resistance is a fundamental factor in the pathogenesis of polycystic ovarian syndrome (PCOS) and has been found to mediate a close association with obesity and dyslipidemia. While the...
9.
Boyce I, DeVoe J, Norsen L, Smith J, Anson E, McGregor H, et al.
Healthcare (Basel)
. 2024 Dec;
12(23).
PMID: 39684980
Background: Evidence for the effectiveness and cost-savings of workplace wellness programs (WWPs) is varied, likely due to the variability in program design, as not all WWPs meet the five-point criteria...
10.
Mitra A, Bhuyan G, Muralikrishna C, Naser S, Ratha K, Babu G, et al.
J Vector Borne Dis
. 2024 Dec;
PMID: 39636260
Background Objectives: A 2.5-year placebo controlled double blind trial was conducted to investigate the safety and efficacy of AYUSH- SL, a poly- herbal Ayurvedic formulation on filarial lymphedema in different...